Fate Therapeutics Inc (FATE)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Fate Therapeutics Inc (FATE)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH137961D
  • |
  • Pages: 47
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Fate Therapeutics Inc (Fate Therapeutics) is a biopharmaceutical company that develops programmed cellular therapeutics for treatment of life threatening diseases. The company's pipeline products encompass immuno-oncology therapies, such as off-the-shelf NK and T-cell-based candidates; and immuno-regulatory therapies, including hematopoietic cell-based candidates. Its products are derived from pluripotent cells. Fate Therapeutics focuses on assisting the immune system of patients undergoing hematopoietic cell transplantation and for inhibiting autoimmunity. It uses ex vivo cell programming approach to include cell-surface proteins, rapid and supra-physiologic activation or inhibition of therapeutically-relevant genes; and to regulate the therapeutic function. Fate Therapeutics is headquartered in San Diego, California, the US.

Fate Therapeutics Inc (FATE)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Fate Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Fate Therapeutics Raises US$20 Million In Venture financing 12

Fate Therapeutics Raises US$9.2 Million In Venture financing 12

Fate Therapeutics Secures Venture Financing 13

Fate Therapeutics Secures US$1 Million In Venture Financing 14

Fate Therapeutics Raises US$36 Million In Series B Financing 15

Partnerships 16

Fate Therapeutics Enters into Agreement with Memorial Sloan Kettering Cancer Center 16

Fate Therapeutics Enters into Research Agreement with Regents of the University of Minnesota 17

Fate Therapeutics Enters into Research Agreement with Boston Children's Hospital 17

Licensing Agreements 18

Juno Therapeutics Enters into Research Collaboration and Licensing Agreement with Fate Therapeutics 18

Fate Therapeutics Enters into Licensing Agreement with Board of Trustees of the Leland Stanford Junior University 19

Equity Offering 20

Fate Therapeutics to Raise Funds through Public Offering of Shares 20

Fate Therapeutics to Raise USD37.5 Million in Private Placement of Preferred Stock 21

Fate Therapeutics to Raise USD19.3 Million in Private Placement of Shares 23

Fate Therapeutics Plans to Raise up to USD12.4 Million in Public Offering of Shares 24

Fate Therapeutics to Raise USD10.3 Million in Private Placement of Shares 25

Fate Therapeutics Raises USD34.5 Million in Public Offering of Shares 26

Fate Therapeutics Completes IPO For US$46 Million 27

Fate Therapeutics Inc-Key Competitors 29

Key Employees 30

Locations And Subsidiaries 31

Head Office 31

Other Locations & Subsidiaries 31

Recent Developments 32

Financial Announcements 32

Mar 16, 2017: Fate Therapeutics Reports Fourth Quarter 2016 Financial Results 32

Nov 07, 2016: Fate Therapeutics Reports Third Quarter 2016 Financial Results 34

Aug 08, 2016: Fate Therapeutics Reports Second Quarter 2016 Financial Results 36

May 09, 2016: Fate Therapeutics Reports First Quarter 2016 Financial Results 38

Mar 03, 2016: Fate Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results 39

Corporate Communications 41

May 17, 2016: Fate Therapeutics Appoints Chris M. Storgard, M.D. as Chief Medical Officer 41

Product Approvals 42

Sep 26, 2016: Fate Therapeutics Receives FDA Orphan Drug Designation for ProTmune in Allogeneic Hematopoietic Cell Transplantation 42

Jan 26, 2016: Fate Therapeutics Announces FDA Clearance of Investigational New Drug Application for ProTmune for Prevention of Acute GvHD and CMV Infection 43

Clinical Trials 44

Jun 11, 2016: Fate Therapeutics Announces Preclinical Data from Immuno-Regulatory CD34+ Cell Therapy for Autoimmune Diseases 44

May 16, 2016: Fate Therapeutics Announces Preclinical Data Highlighting Persistent Effector Function of Allogeneic Natural Killer Cell Cancer Immunotherapy 45

Feb 21, 2016: Fate Therapeutics to Present Preclinical Data for ProTmune at 2016 BMT Tandem Meetings 46

Appendix 47

Methodology 47

About GlobalData 47

Contact Us 47

Disclaimer 47

List of Figures

Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

List of Tables

Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 1

Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Fate Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Fate Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9

Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Fate Therapeutics Raises US$20 Million In Venture financing 12

Fate Therapeutics Raises US$9.2 Million In Venture financing 12

Fate Therapeutics Secures Venture Financing 13

Fate Therapeutics Secures US$1 Million In Venture Financing 14

Fate Therapeutics Raises US$36 Million In Series B Financing 15

Fate Therapeutics Enters into Agreement with Memorial Sloan Kettering Cancer Center 16

Fate Therapeutics Enters into Research Agreement with Regents of the University of Minnesota 17

Fate Therapeutics Enters into Research Agreement with Boston Children's Hospital 17

Juno Therapeutics Enters into Research Collaboration and Licensing Agreement with Fate Therapeutics 18

Fate Therapeutics Enters into Licensing Agreement with Board of Trustees of the Leland Stanford Junior University 19

Fate Therapeutics to Raise Funds through Public Offering of Shares 20

Fate Therapeutics to Raise USD37.5 Million in Private Placement of Preferred Stock 21

Fate Therapeutics to Raise USD19.3 Million in Private Placement of Shares 23

Fate Therapeutics Plans to Raise up to USD12.4 Million in Public Offering of Shares 24

Fate Therapeutics to Raise USD10.3 Million in Private Placement of Shares 25

Fate Therapeutics Raises USD34.5 Million in Public Offering of Shares 26

Fate Therapeutics Completes IPO For US$46 Million 27

Fate Therapeutics Inc, Key Competitors 29

Fate Therapeutics Inc, Key Employees 30

Fate Therapeutics Inc, Subsidiaries 31

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Fate Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16143
Site License
USD 500 INR 32285
Corporate User License
USD 750 INR 48428

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com